L10 ANSWER 1 OF 4 USPATFULL on STN ΝA 2004:120135 USPATFULL ΤI Solid matrix therapeutic compositions Unger, Evan C., Tucson, AZ, UNITED STATES IN A1 PΙ US 2004091541 20040513 US 2003-622027 Α1 20030716 (10) AΙ Continuation of Ser. No. US 2001-828762, filed on 9 Apr 2001, ABANDONED RLI Division of Ser. No. US 1998-75477, filed on 11 May 1998, ABANDONED US 1997-46379P 19970513 (60) PRAI Utility DТ APPLICATION FS LREP REED & EBERLE LLP, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025 CLMN Number of Claims: 38 Exemplary Claim: 1 ECL 1 Drawing Page(s) DRWN LN.CNT 4909 CAS INDEXING IS AVAILABLE FOR THIS PATENT. The present invention is directed to a solid porous matrix comprising a AB surfactant in combination with a bioactive agent. The solid porous matrix may be prepared by combining a surfactant and a therapeutic, together with a solvent, to form an emulsion containing random aggregates of the surfactant and the therapeutic, and processing the emulsion by controlled drying, or controlled agitation and controlled drying to form the solid porous matrix. CAS INDEXING IS AVAILABLE FOR THIS PATENT. L10 ANSWER 2 OF 4 USPATFULL on STN 2002:72457 USPATFULL AN SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME TΙ UNGER, EVAN C., TUCSON, AZ, UNITED STATES IN US 2002039594 A1 20020404 PΙ AΙ US 1998-75477 A1 19980511 (9) 19970513 (60) US 1997-46379P PRAI DTUtility APPLICATION WOODCOCK WASHBURN KURTZ, MACKIEWICZ AND NORRIS, ONE LIBERTY PLACE 46TH LREP FLOOR, PHILADELPHIA, PA, 19103 CLMN Number of Claims: 106 ECL Exemplary Claim: 1 DRWN 1 Drawing Page(s) LN.CNT 5207 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

The present invention is directed to a solid porous matrix comprising a AΒ solvent and a surfactant in combination with a bioactive agent. The solvent and the surfactant may, if desired, form vesicles, an agglomeration of which comprises the matrix. The composition optionally comprises a gas or a gaseous precursor. The emulsion may be dried, and subsequently reconstituted in an aqueous or organic solution.

The present invention is also directed to a method of preparing a solid porous matrix comprising combining a solvent, a surfactant, and a therapeutic to form an emulsion; and processing the emulsion by controlled drying, or controlled agitation and controlled drying to form a solid porous matrix. The resulting solid porous matrix may also comprise a gas or gaseous precursor and be added to a resuspending medium.

A method for the controlled delivery of a targeted therapeutic to a region of a patient is another embodiment of the present invention. The method comprises administering to the patient a composition having a solid porous matrix comprising a solvent, a surfactant, a therapeutic, and a gas or gaseous precursor, monitoring the composition using energy to determine the presence of the composition in the region; and releasing the therapeutic from the composition in the region using energy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
ANSWER 3 OF 4 USPATFULL on STN
L10
       2001:144937 USPATFULL
AN
       Solid matrix therapeutic compositions
TT
       Unger, Evan C., Tucson, AZ, United States
IN
       ImaRx Therapeutics, Inc. (U.S. corporation)
PΑ
                             20010830
       US 2001018072
                          A1
PΙ
       US 2001-828762
                          A1 20010409 (9)
ΑI
       Division of Ser. No. US 1998-75477, filed on 11 May 1998, PENDING
RLI
       US 1997-46379P
                           19970513 (60)
PRAI
       Utility
DT
      APPLICATION
FS
       Mackiewicz & Norris LLP, One Liberty Place - 46th Floor, Philadelphia,
LREP
       PA, 19103
       Number of Claims: 38
CLMN
       Exemplary Claim: 1
ECL
       1 Drawing Page(s)
DRWN
LN.CNT 4899
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       The present invention is directed to a solid porous matrix comprising a
AB
       surfactant in combination with a bioactive agent. The solid porous
       matrix may be prepared by combining a surfactant and a therapeutic,
       together with a solvent, to form an emulsion containing random
       aggregates of the surfactant and the therapeutic, and processing the
       emulsion by controlled drying, or controlled agitation and controlled
       drying to form the solid porous matrix.
```

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
ANSWER 4 OF 4 USPATFULL on STN
T-10-
ΑN
       1998:19285 USPATFULL
ΤI
       Process for recovering sulfur hexafluoride
       Yates, Stephen Frederic, Arlington Heights, IL, United States
IN
       Gaita, Romulus, Morton Grove, IL, United States
       Ramachandra, Amar, Bensenville, IL, United States
       Morrell, Robert, Des Plaines, IL, United States
AlliedSignal Inc., Morristown, NJ, United States (U.S. corporation)
PΑ
       US 5720797
                                 19980224
PΙ
       US 1996-769022
                                 19961218 (8)
ΑI
DT
       Utility
FS
       Granted
EXNAM Primary Examiner: Spitzer, Robert
       Gianneschi, Lois A.
LREP
CLMN
       Number of Claims: 25
       Exemplary Claim: 1
ECL
DRWN
       No Drawings
LN.CNT 505
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       The present invention relates to a process for recovering sulfur
       hexafluoride ("SF.sub.6"). More specifically, the invention provides a
       pressure swing adsorption--desorption process for recovering SF.sub.6
       from a gas stream using zeolites, activated carbons, or
       silicalites to adsorb the SF.sub.6.
```

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
L13 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 1
      2001:816601 CAPLUS
ΑN
DN
      135:346144
      Adsorptive method for purification of tetrafluoromethane and its
TΙ
      Ohno, Hiromoto; Ohi, Toshio
IN
PA
      Showa Denko K. K., Japan
      PCT Int. Appl., 20 pp.
SO
      CODEN: PIXXD2
DТ
      Patent
      English
LΑ
FAN.CNT 2
                                                      APPLICATION NO.
                                                                                  DATE
      PATENT NO.
                              KIND
                                       DATE
      WO 2001083412
                                       20011108
                                                      WO 2001-JP3664
                                                                                   20010426
                               A2
PΙ
           W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
          W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                                       20011031
                                                     JP 2000-128681
                                                                                   20000428
      JP 2001302566
                               Α2
                                       20011112
                                                      AU 2001-52617
                                                                                   20010426
      AU 2001052617
                               Α5
                               C2
                                       20031110
                                                      RU 2002-101934
                                                                                   20010426
      RU 2215730
PRAI JP 2000-128681
                               Α
                                       20000428
                               Ρ
                                       20000907
      US 2000-230704P
                               W
                                       20010426
      WO 2001-JP3664
      Tetrafluoromethane, containing ethylene compds., hydrocarbon compds.,
AB
      carbon monoxide, and/or carbon dioxide
      , is purified by contacting it with zeolites having an
      average pore size of 3.4-11 Å and a Si/Al ratio of
      ≤1.5 and/or a carbonaceous adsorbent having an average
      pore size of 3.4-11 Å.
      ANSWER 11 OF 14 USPATFULL on STN
L13
AN
        2000:145865 USPATFULL
        Targeted contrast agents for diagnostic and therapeutic use
TI
        Unger, Evan C., Tucson, AZ, United States
IN
        Fritz, Thomas A., Tucson, AZ, United States
        Gertz, Edward W., Paradise Valley, AZ, United States
        ImaRx Pharmaceutical Corp., Tucson, AZ, United States (U.S. corporation)
PA
PΙ
        US 6139819
                                     20001031
ΑI
        US 1997-932273
                                      19970917 (8)
        Continuation-in-part of Ser. No. US 1996-660032, filed on 6 Jun 1996,
RLT
        now abandoned which is a continuation-in-part of Ser. No. US
        1996-640464, filed on 1 May 1996, now abandoned which is a
        continuation-in-part of Ser. No. US 1995-497684, filed on 7 Jun 1995,
        now abandoned And a continuation-in-part of Ser. No. US 1996-666129,
        filed on 19 Jun 1996, now patented, Pat. No. US 6033645
DT
        Utility
FS
        Granted
        Primary Examiner: Dees, Jose' G.; Assistant Examiner: Hartley, Michael
EXNAM
        Woodcock Washburn Kurtz Mackiewicz & Norris LLP
LREP
        Number of Claims: 174
CLMN
ECL
        Exemplary Claim: 1
        1 Drawing Figure(s); 1 Drawing Page(s)
DRWN
LN.CNT 7523
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
        Novel contrast agents which may be used for diagnostic and therapeutic
```

use. The compositions may comprise a lipid, a protein, polymer and/or surfactant, and a gas, in combination with a targeting ligand. In preferred embodiments, the targeting ligand targets coagula, including emboli and/or thrombi, particularly in patients suffering from an arrhythmic disorder. The contrast media can be used in conjunction with diagnostic imaging, such as ultrasound, as well as therapeutic applications, such as therapeutic ultrasound.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

1999:3743 USPATFULL Process and system for separation and recovery of perfluorocompound Li, Yao-En, Buffalo Grove, IL, United States TN Paganessi, Joseph E., Burr Ridge, IL, United States Vassallo, David, Glenview, IL, United States Fleming, Gregory K., Wilmington, DE, United States American Air Liquide, Walnut Creek, CA, United States (U.S. corporation) PA 19990112 ΡI US 5858065 19970116 (8) US 1997-783949 ΑI Continuation-in-part of Ser. No. US 1996-665142, filed on 14 Jun 1996 RLIDT Utility Granted Primary Examiner: Spitzer, Robert EXNAM Burns, Doane, Swecker & Mathis, L.L.P. LREP Number of Claims: 77 CLMN Exemplary Claim: 1 ECL 15 Drawing Figure(s); 13 Drawing Page(s) DRWN LN.CNT 1681 CAS INDEXING IS AVAILABLE FOR THIS PATENT. Processes and systems to recover at least one perfluorocompound gas from AΒ a gas mixture are provided. In one embodiment the inventive process comprises providing a gas mixture comprising at least one perfluorocompound gas and at least one carrier gas, the gas mixture being at a predetermined pressure; providing at least one size selective membrane having a feed side and a permeate side; contacting the feed side of the at least one membrane with the gas mixture; withdrawing from the feed side of the membrane as a non-permeate stream at a pressure which is substantially equal to the predetermined pressure a concentrated gas mixture comprising essentially the at least one perfluorocompound gas; and withdrawing from the permeate side of the membrane as a permeate stream a depleted gas mixture comprising essentially the at least one carrier gas.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 14 OF 14 USPATFULL on STN

```
ANSWER 2 OF 3 USPATFULL on STN
L17
AN
       2000:9374 USPATFULL
       Method of processing semiconductor manufacturing exhaust gases
TТ
       Ji, Wenchang, Doylestown, PA, United States
TN
       Shen, Dongmin, Chatham, NJ, United States
       Jain, Ravi, Bridgewater, NJ, United States
       Shirley, Arthur I., Piscataway, NJ, United States
       Athalye, Atul M., Chatham, NJ, United States
       Sadkowski, Piotr J., Bridgewater, NJ, United States
       The BOC Group, Inc., New Providence, NJ, United States (U.S.
PA
       corporation)
                               20000125
       US 6017382
PΙ
       US 1998-50259
                               19980330 (9)
AΙ
       Utility
DΤ
       Granted
FS
       Primary Examiner: Spitzer, Robert
EXNAM
       Rosenblum, David M., Pace, Salvatore P.
LREP
       Number of Claims: 13
CLMN
       Exemplary Claim: 1
ECL
       2 Drawing Figure(s); 1 Drawing Page(s)
DRWN
LN.CNT 452
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       A method of processing semiconductor manufacturing exhaust gases for
       recovering at least hexafluoroethane in which a feed stream composed of
       the exhaust gases is passed through an adsorbent bed selected
       to adsorb oxygen, and also nitrogen if present, but not to
       appreciably adsorb the hexafluoroethane. As a result, a
       product stream, discharged from the adsorbent bed, has a
       higher concentration of hexafluoroethane than in the feed stream. In one
       embodiment, only a single adsorbent such as carbon molecular
       sieve is provided to adsorb the oxygen or a modified 4A
       zeolite could be used to adsorb both oxygen and
       nitrogen. When nitrogen is a potential constituent, layers of carbon
       molecular sieve and zeolite are provided to adsorb
       the oxygen and then the nitrogen, respectively. A third
       adsorbent, preferably 5A zeolite may be provided in
       addition to the foregoing two adsorbents to also
       adsorb any carbon tetrafluoride produced as a by-product.
```

```
ANSWER 6 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 3
     1996:365345 CAPLUS
DΝ
     125:33156
     Purification of tetrafluoromethane
    Oono, Hiromoto; Nakajo, Tetsuo; Ooi, Toshio
     Showa Denko Kk, Japan
    Jpn. Kokai Tokkyo Koho, 3 pp.
     CODEN: JKXXAF
     Patent
LΑ
     Japanese
FAN.CNT 1
                                            APPLICATION NO.
                                                                   DATE
                         KIND
                                DATE
     PATENT NO.
     ______
                         _ _ _ _
                                                                   19940908
    JP 08081399
                          A2
                                19960326
                                            JP 1994-214861
                                19990726
     JP 2924660
                          B2
                                19940908
PRAI JP 1994-214861
    CF3-containing CF4 is purified by treating with zeolites or
     carbonaceous adsorbents having pore size 3.5-11 Å.
     A cylinder containing zeolites having pore size
     4 Å was treated with 12,000 ppm CF3-containing CF4 at room temperature for 20 h
     to recover <10 ppm CF3-containing CF4.
L21 ANSWER 7 OF 9 USPATFULL on STN
       91:98193 USPATFULL
AN
      Method of refining nitrogen trifluoride gas
TI
      Suenaga, Takashi, Yamaguchi, Japan
      Fujii, Tukasa, Ube, Japan
      Kobayashi, Yoshiyuki, Ube, Japan
      Central Glass Company, Limited, Ube, Japan (non-U.S. corporation)
PA
                               19911203
      US 5069887
PI
                               19910110 (7)
      US 1991-639541
ΑI
      JP 1990-3112
                          19900110
PRAI
      Utility
DT
      Granted
FS
EXNAM Primary Examiner: Lewis, Michael; Assistant Examiner: Bolam, Brian M.
      Fleit, Jacobson, Cohn, Price, Holman & Stern
LREP
      Number of Claims: 7
CLMN
ECL
       Exemplary Claim: 1
       1 Drawing Figure(s); 1 Drawing Page(s)
DRWN
LN.CNT 249
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       The invention provides a selective adsorption method for refining
AΒ
       NF.sub.3 gas containing CF.sub.4 as impurity. At a temperature not
       higher than 10° C. the NF.sub.3 gas is brought into contact with
       a crystalline and porous synthetic zeolite, which is
       substantially uniform in pore size and about 4.9
       A in effective pore size and is commerciallized
       under the name of molecular sieve 5A, on condition that the content of
       water of crystallinity in the synthetic zeolite is 1-10 weight %,
       and preferably 6-10 weight %. The synthetic zeolite efficiently
       adsorbs NF.sub.3 with little adsorption of CF.sub.4.
```

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

(FILE 'HOME' ENTERED AT 13:47:48 ON 09 NOV 2004)

FILE 'REGISTRY' ENTERED AT 13:48:12 ON 09 NOV 2004 1 S TETRAFLUOROMETHANE/CN

L1

	FILE 'CAPL'	US, USPATFULL, CA, CAOLD' ENTERED AT 13:49:07 ON 09 NOV 2004
L2	25773	
L3	294	S L2 AND ZEOLITE
L4	0	S L3 AND PORE SIXE
L5	39	S L3 AND PORE SIZE
L6	27	S L5 AND CARBON ?OXIDE
L7	22	S L6 AND ADSORB?
L8	4	S L7 AND IMPURIT?
L9	4	S L8 AND PURIF?
L10	4	DUP REM L9 (0 DUPLICATES REMOVED)
L11	18	S L7 NOT L10
L12		
L13		DUP REM L12 (1 DUPLICATE REMOVED)
L14		S L13 AND IMPURIT?
L15		S L7 NOT L12
L16		S L15 NOT L10
L17	3	DUP REM L16 (0 DUPLICATES REMOVED)
L18		S L6 NOT L7
L19		DUP REM L18 (0 DUPLICATES REMOVED)
L20		S L5 NOT L6
L21	9	DUP REM L20 (3 DUPLICATES REMOVED)